Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia.
Crohn's disease
adalimumab
biosimilar
inflammatory bowel disease
infliximab
ulcerative colitis
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
13
12
2018
revised:
05
02
2019
accepted:
02
03
2019
pubmed:
9
3
2019
medline:
11
2
2020
entrez:
9
3
2019
Statut:
ppublish
Résumé
The Asia-Pacific Working Group on Inflammatory Bowel Disease was established in Cebu, Philippines, under the auspices of the Asia-Pacific Association of Gastroenterology with the goal of improving inflammatory bowel disease care in Asia. This consensus is carried out in collaboration with Asian Organization for Crohn's and Colitis. With biologic agents and biosimilars becoming more established, it is necessary to conduct a review on existing literature and establish a consensus on when and how to introduce biologic agents and biosimilars in conjunction with conventional treatments for ulcerative colitis and Crohn's disease in Asia. These statements also address how pharmacogenetics influences the treatments of ulcerative colitis and Crohn's disease and provides guidance on response monitoring and strategies to restore loss of response. Finally, the review includes statements on how to manage treatment alongside possible hepatitis B and tuberculosis infections, both common in Asia. These statements have been prepared and voted upon by members of inflammatory bowel disease workgroup employing the modified Delphi process. These statements do not intend to be all-encompassing, and future revisions are likely as new data continue to emerge.
Substances chimiques
Biological Products
0
Immunologic Factors
0
Types de publication
Consensus Development Conference
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1296-1315Subventions
Organisme : JGH Foundation
ID : 2017
Informations de copyright
© 2019 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Ooi CJ, Makharia GK, Hilmi I et al. Asia Pacific consensus statements on Crohn's disease. Part 1: definition, diagnosis, and epidemiology: (Asia Pacific Crohn's disease consensus-part 1). J. Gastroenterol. Hepatol. 2016; 31: 45-55.
Ooi CJ, Makharia GK, Hilmi I et al. Asia-Pacific consensus statements on Crohn's disease. Part 2: management. J. Gastroenterol. Hepatol. 2016; 31: 56-68.
Linstone AH, Turoff M. The Delphi method: techniques and applications. Dent. Tech. 1975; 18.
Canadian Task Force on the Periodic, Examination H. The period health examination. Cma. 1979; 121: 1193-1254.
Renna S, Cottone M, Orlando A. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. World J. Gastroenterol. 2014: 9675-9690.
Sandborn WJ. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology 2008; 135: 1442-1447.
Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005; 128: 862-869.
Colombel JF, Rutgeerts PJ, Sandborn WJ et al. Adalimumab induces deep remission in patients with Crohn's disease. Clin. Gastroenterol. Hepatol. 2014; 12: 414-422.
D'Haens G, Van Deventer S, Van Hogezand R et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999; 116: 1029-1034.
Rutgeerts P, Van Assche G, Sandborn WJ et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012 May; 142: 1102-1111 e2.
Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549.
Colombel J-F, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
Schreiber S. Certolizumab pegol for the treatment of Crohn's disease. Therap. Adv. Gastroenterol. 2011; 4: 375-389.
Schreiber S, Khaliq-Kareemi M, Lawrance IC et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N. Engl. J. Med. 2007; 357: 239-250.
Orlando A, Armuzzi A, Papi C et al. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) clinical practice guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Dig. Liver Dis. 2011; 43: 1-20.
Sandborn WJ, Feagan BG, Rutgeerts P et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 2013; 369: 711-721.
Sands BE, Feagan BG, Rutgeerts P et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014; 147: 618-627.
Gomollón F, Dignass A, Annese V et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 1: diagnosis and medical management. J. Crohns Colitis 2017; 11: 3-25.
Sandborn WJ, Gasink C, Gao L-L et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N. Engl. J. Med. 2012; 367: 1519-1528.
Chen QQ, Yan L, Wan J. Select a suitable treatment strategy for Crohn's disease: step-up or top-down. EXCLI J. 2014; 13: 111-122.
D'Haens GR. Top-down therapy for IBD: rationale and requisite evidence. Nat. Rev. Gastroenterol. Hepatol. 2010; 7: 86-92.
Navarra SV, Tang B, Lu L et al. Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in Asia. Int. J. Rheum. Dis. 2014; 17: 291-298.
Wei SC. Differences in the public medical insurance systems for inflammatory bowel disease treatment in Asian countries. Intest Res. 2016; 14: 218.
Lin MV, Blonski W, Lichtenstein GR. What is the optimal therapy for Crohn's disease: step-up or top-down? Expert Rev. Gastroenterol. Hepatol. 2010; 4: 167-180.
Shergill AK, Terdiman JP. Controversies in the treatment of Crohn's disease: the case for an accelerated step-up treatment approach. World J. Gastroenterol. 2008; 14: 2670-2677.
Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology 2006; 130: 650-656.
Sands B. Risk of early surgery for Crohn's disease: implications for early treatment strategies. Am. J. Gastroenterol. 2003; 98: 2712-2718.
Miheller P, Kiss LS, Juhasz M, Mandel M, Lakatos PL. Recommendations for identifying Crohn's disease patients with poor prognosis. Expert Rev. Clin. Immunol. 2013; 9: 65-76.
Aniwan S, Park SH, Loftus EV. Epidemiology, natural history, and risk stratification of Crohn's disease. Gastroenterol. Clin. North Am. 2017; 46: 463-480.
Mahid SS, Minor KS, Stevens PL, Galandiuk S. The role of smoking in Crohn's disease as defined by clinical variables. Dig. Dis. Sci. 2007; 52: 2897-2903.
Sandborn WJ. Crohn's disease evaluation and treatment: clinical decision tool. Gastroenterology 2014; 147: 702-703.
Oh EH, Oh K, Han M et al. Early anti-TNF/immunomodulator therapy is associated with better long-term clinical outcomes in Asian patients with Crohn's disease with poor prognostic factors. PLoS ONE 2017; 12: 1-17.
D'Haens G, Baert F, van Assche G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-667.
Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 2010; 362: 1383-1395.
Panaccione R, Ghosh S, Middleton S et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014; 146: 392-400.
Jones JL, Kaplan GG, Peyrin-Biroulet L et al. Effects of concomitant immunomodulator therapy on efficacy and safety of anti-tumor necrosis factor therapy for Crohn's disease: a meta-analysis of placebo-controlled trials. Clin. Gastroenterol. Hepatol. 2015; 13: 2233-2240 e2.
Colombel JF, Jharap B, Sandborn WJ et al. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy. Aliment. Pharmacol. Ther. 2017; 45: 50-62.
Ben-Horin S, Waterman M, Kopylov U et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2013; 11: 444-447.
Strik AS, van den Brink GR, Ponsioen C, Mathot R, Löwenberg M, D'Haens GR. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2017; 45: 1128-1134.
Feagan BG, McDonald JWD, Panaccione R et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology 2014; 146: 681-688.
Van Assche G, Magdelaine-Beuzelin C, D'Haens G et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134: 1861-1868.
Roblin X, Boschetti G, Williet N et al. Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial. Aliment. Pharmacol. Ther. 2017; 46: 142-149.
Bots S, Gecse K, Barclay M, D'Haens G. Combination immunosuppression in IBD. Inflamm. Bowel Dis. 2018; 24: 539-545.
Hanauer SB, Wagner CL, Bala M et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin. Gastroenterol. Hepatol. 2004; 2: 542-553.
Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med. 2004; 350: 876-885.
Torres J, Boyapati RK, Kennedy NA, Louis E, Colombel JF, Satsangi J. Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease. Vol. 149. Gastroenterology 2015: 1716-1730.
Louis E, Mary JY, Verniermassouille G et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142: 63-70.
Frias Gomes C, Colombel JF, Torres J. De-escalation of therapy in inflammatory bowel disease. Curr. Gastroenterol. Rep. 2018 Jul; 20: 35.
Sorrentino D, Paviotti A, Terrosu G, Avellini C, Geraci M, Zarifi D. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. Clin. Gastroenterol. Hepatol. [Internet] 2010 Jul 1; 8: 591-599.e1.
Van Steenbergen S, Bian S, Vermeire S, Van Assche G, Gils A, Ferrante M. Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease-a nested case-control study. Aliment. Pharmacol. Ther. 2017; 45: 923-932.
Kawalec P, Mikrut A, Wiśniewska N, Pilc A. Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis. Arch. Med. Sci. 2013; 9: 765-779.
Feagan BG, Schwartz D, Danese S et al. Efficacy of vedolizumab in fistulising Crohn's disease: exploratory analyses of data from GEMINI 2. J. Crohns Colitis 2018; 12: 621-626.
Ji C-C, Takano S. Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn's disease. Intest. Res. 2017; 15: 182.
Panés J, García-Olmo D, Van Assche G et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet 2016; 388: 1281-1290.
Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 2005; 353: 2462-2476.
Sandborn WJ, Van Assche G, Reinisch W et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-265.
Sandborn WJ, Feagan BG, Marano C et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 85-95.
Sandborn WJ, Feagan BG, Marano C et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 96-109.
Feagan BG, Rutgeerts P, Sands BE et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 2013; 369: 699-710.
Järnerot G, Hertervig E, Friis-Liby I et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805-1811.
García-López S, Gomollón-García F, Pérez-Gisbert J. Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review. Gastroenterol. Hepatol. 2005; 28: 607-614.
Laharie D, Bourreille A, Branche J et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380: 1909-1915.
Williams JG, Alam MF, Alrubaiy L et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial. Lancet Gastroenterol. Hepatol. 2016; 1: 15-24.
Chen J-H, Andrews JM, Kariyawasam V et al. Review article: acute severe ulcerative colitis-evidence-based consensus statements. Aliment. Pharmacol. Ther. 2016; 44: 127-144.
Peyrin-Biroulet L, Van Assche G, Gómez-Ulloa D et al. Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2017; 15: 25-36.e27.
Tadbiri S, Peyrin-Biroulet L, Serrero M et al. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. Aliment. Pharmacol. Ther. 2018; 47: 485-493.
Colombel J-F, Sands BE, Rutgeerts P et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut 2017; 66: 839-851.
Amiot A, Serrero M, Peyrin-Biroulet L et al. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment. Pharmacol. Ther. 2017; 46: 310-321.
Sands BE, Sandborn WJ, Van Assche G et al. Vedolizumab as induction and maintenance therapy for Crohn's disease in patients naïve to or who have failed tumor necrosis factor antagonist therapy. Inflamm. Bowel Dis. 2017; 23: 97-106.
Gottlieb AB, Kalb RE, Langley RG et al. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. J. Drugs Dermatol. 2014; 13: 1441-1448.
Tsai TF, Ho V, Song M et al. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br. J. Dermatol. 2012; 167: 1145-1152.
Papp K, Gottlieb AB, Naldi L et al. Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J. Drugs Dermatol. 2015; 14: 706-714.
McInnes IB, Kavanaugh A, Gottlieb AB et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013; 382: 780-789.
Ritchlin C, Rahman P, Kavanaugh A et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann. Rheum. Dis. 2014 Jun; 73: 990-999.
Lynch M, Roche L, Horgan M, Ahmad K, Hackett C, Ramsay B. Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis. JAAD Case Reports. 2017; 3: 230-232.
Sánchez-Moya AI, Daudén E. Peripheral lymph node recurrence of tuberculosis after ustekinumab treatment. Arch. Dermatol. 2012; 148: 1332-1333.
Scott FI, Lichtenstein GR. Biosimilars in the treatment of inflammatory bowel disease: supporting evidence in 2017. Curr. Treat. Options Gastroenterol. 2018; 16: 147-164.
Avila-Ribeiro P, Fiorino G, Danese S. The experience with biosimilars of infliximab in inflammatory bowel disease. Curr. Pharm. Des. 2017; 23: 6759-6769.
Cohen HP, Blauvelt A, Rifkin RM, Danese S, Gokhale SB, Woollett G. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs 2018; 78: 463-478.
Fiorino G, Manetti N, Armuzzi A et al. The PROSIT-BIO cohort: a prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar. Inflamm. Bowel Dis. 2017; 23: 233-243.
Schmitz EMH, Boekema PJ, Straathof JWA et al. Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study. Aliment. Pharmacol. Ther. 2018; 47: 356-363.
Park SH, Kim YH, Lee JH et al. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev. Gastroenterol. Hepatol. 2015; 9: S35-S44.
Kurti Z, Gonczi L, Lakatos PL. Progress with infliximab biosimilars for inflammatory bowel disease. Expert Opin. Biol. Ther. 2018 Jun; 18: 633-640.
Peyrin-Biroulet L, Sandborn W, Sands BE et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am. J. Gastroenterol. 2015; 110: 1324-1338.
Levesque BG, Sandborn WJ, Ruel J, Feagan BG, Sands BE, Colombel JF. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology 2015; 148: 37-51.
Walsh AJ, Bryant RV, Travis SPL. Current best practice for disease activity assessment in IBD. Nat. Rev. Gastroenterol. Hepatol. 2016; 13: 567-579.
Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-444.
Thia KT, Sandborn WJ, Lewis JD et al. Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease. Am. J. Gastroenterol. 2008; 103: 3123-3131.
Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980; 315: 514.
Sandborn WJ, Sands BE, Wolf DC et al. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment. Pharmacol. Ther. 2003 Jun; 17: 1355-1364.
Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N. Engl. J. Med. 1987; 317: 1625-1629.
Frøslie KF, Jahnsen J, Moum BA, Vatn MH. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-422.
Rutgeerts P, Diamond RH, Bala M et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest. Endosc. 2006; 63: 433-442.
Schnitzler F, Fidder H, Ferrante M et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm. Bowel Dis. 2009; 15: 1295-1301.
Colombel JF, Rutgeerts P, Reinisch W et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141: 1194-1201.
Jones J, Loftus EV, Panaccione R et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin. Gastroenterol. Hepatol. 2008; 6: 1218-1224.
Peyrin-Biroulet L, Reinisch W, Colombel JF et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut 2014; 63: 88-95.
Boschetti G, Garnero P, Moussata D et al. Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease. Inflamm. Bowel Dis. 2015; 21: 331-336.
Vermeire S. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut 2014; 63: 1721-1727.
Molander P, Af Björkesten CG, Mustonen H et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflamm. Bowel Dis. 2012; 18: 2011-2017.
Kiss LS, Szamosi T, Molnar T et al. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease. Aliment. Pharmacol. Ther. 2011; 34: 911-922.
Guidi L, Marzo M, Andrisani G et al. Faecal calprotectin assay after induction with anti-tumour necrosis factor α agents in inflammatory bowel disease: prediction of clinical response and mucosal healing at one year. Dig. Liver Dis. 2014; 46: 974-979.
Iwasa R, Yamada A, Sono K, Furukawa R, Takeuchi K, Suzuki Y. C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study. BMC Gastroenterol. 2015; 15: 103.
Panes J, Bouhnik Y, Reinisch W et al. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J. Crohns Colitis 2013; 7: 556-585.
Efthymiou A, Viazis N, Mantzaris G et al. Does clinical response correlate with mucosal healing in patients with Crohn's disease of the small bowel? A prospective, case-series study using wireless capsule endoscopy. Inflamm. Bowel Dis. 2008; 14: 1542-1547.
Hall B, Holleran G, Chin JL et al. A prospective 52 week mucosal healing assessment of small bowel Crohn's disease as detected by capsule endoscopy. J. Crohns Colitis 2014; 8: 1601-1609.
Hall BJ, Holleran GE, Smith SM, Mahmud N, McNamara DA. A prospective 12-week mucosal healing assessment of small bowel Crohn's disease as detected by capsule endoscopy. Eur. J. Gastroenterol. Hepatol. 2014; 26: 1253-1259.
Kopylov U, Yablecovitch D, Lahat A et al. Detection of small bowel mucosal healing and deep remission in patients with known small bowel Crohn's disease using biomarkers, capsule endoscopy, and imaging. Am. J. Gastroenterol. 2015; 110: 1316-1323.
Yang L, Ge ZZ, Gao YJ et al. Assessment of capsule endoscopy scoring index, clinical disease activity, and C-reactive protein in small bowel Crohn's disease. J. Gastroenterol. Hepatol. 2013; 28: 829-833.
Carvalho PB, Rosa B, Cotter J. Mucosal healing in Crohn's disease-are we reaching as far as possible with capsule endoscopy? J. Crohns Colitis 2014; 8: 1566-1567.
Niv Y. Small-bowel mucosal healing assessment by capsule endoscopy as a predictor of long-term clinical remission in patients with Crohn's disease. Eur. J. Gastroenterol. Hepatol. 2017; 29: 844-848.
Kopylov U, Yung DE, Engel T et al. Diagnostic yield of capsule endoscopy versus magnetic resonance enterography and small bowel contrast ultrasound in the evaluation of small bowel Crohn's disease: systematic review and meta-analysis. Dig. Liver Dis. 2017; 49: 854-863.
Cotter J, Dias De Castro F, Magalhães J, Moreira MJ, Rosa B. Validation of the Lewis score for the evaluation of small-bowel Crohn's disease activity. Endoscopy 2015; 47: 330-335.
Niv Y, Ilani S, Levi Z et al. Validation of the Capsule Endoscopy Crohn's Disease Activity Index (CECDAI or Niv score): a multicenter prospective study. Endoscopy 2012 Jan; 44: 21-26.
Enns RA, Hookey L, Armstrong D et al. Clinical practice guidelines for the use of video capsule endoscopy. Gastroenterology 2017; 152: 497-514.
Cheifetz AS, Kornbluth AA, Legnani P et al. The risk of retention of the capsule endoscope in patients with known or suspected Crohn's disease. Am. J. Gastroenterol. 2006; 101: 2218-2222.
Liao Z, Gao R, Xu C, Li ZS. Indications and detection, completion, and retention rates of small-bowel capsule endoscopy: a systematic review. Gastrointest. Endosc. 2010; 71: 280-286.
Postgate AJ, Burling D, Gupta A, Fitzpatrick A, Fraser C. Safety, reliability and limitations of the given patency capsule in patients at risk of capsule retention: a 3-year technical review. Dig. Dis. Sci. 2008; 53: 2732-2738.
Hoog CM, Bark L-A, Arkani J, Gorsetman J, Brostrom O, Sjoqvist U. Capsule retentions and incomplete capsule endoscopy examinations: an analysis of 2300 examinations. Gastroenterol Res Pract. 2012; 2012: 518718.
Ye CA, Gao YJ, Ge ZZ et al. PillCam colon capsule endoscopy versus conventional colonoscopy for the detection of severity and extent of ulcerative colitis. J. Dig. Dis. 2013; 14: 117-124.
Hosoe N, Matsuoka K, Naganuma M et al. Applicability of second-generation colon capsule endoscope to ulcerative colitis: a clinical feasibility study. J. Gastroenterol. Hepatol. 2013; 28: 1174-1179.
Meister T, Heinzow HS, Domagk D et al. Colon capsule endoscopy versus standard colonoscopy in assessing disease activity of ulcerative colitis: a prospective trial. Tech. Coloproctol. 2013; 17: 641-646.
Sung J, Ho KY, Chiu HM, Ching J, Travis S, Peled R. The use of Pillcam Colon in assessing mucosal inflammation in ulcerative colitis: a multicenter study. Endoscopy 2012; 44: 754-758.
Collins PD. Video capsule endoscopy in inflammatory bowel disease. World J Gastrointest Endosc. 2016 Jul; 8: 477-488.
Reenaers C, Mary JY, Nachury M et al. Outcomes 7 years after infliximab withdrawal for patients with Crohn's disease in sustained remission. Clin. Gastroenterol. Hepatol. 2018; 16: 234-243.e2.
Doherty G, Katsanos KH, Burisch J et al. European Crohn's and Colitis Organisation topical review on treatment withdrawal [‘exit strategies’] in inflammatory bowel disease. J. Crohns Colitis 2018 Jan; 12: 17-31.
Treton X, Bouhnik Y, Mary JY et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin. Gastroenterol. Hepatol. 2009; 7: 80-85.
O'Donoghue DP, Dawson AM, Powell-Tuck J, Bown RL, Lennard-Jones JE. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet 1978; 312: 955-957.
Hawthorne AB, Logan RF, Hawkey CJ et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992; 305: 20-22.
Lémann M, Mary JY, Colombel JF et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005; 128: 1812-1818.
Clarke K, Regueiro M. Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm. Bowel Dis. 2012; 18: 174-179.
Pittet V, Froehlich F, Maillard MH et al. When do we dare to stop biological or immunomodulatory therapy for Crohn's disease? Results of a multidisciplinary European expert panel. J. Crohns Colitis 2013; 7: 820-826.
Julien K, Laurent B, Fabrice C, Harry S, Jacques C, Michaël S. Impact on life expectancy of withdrawing thiopurines in patients with Crohn's disease in sustained clinical remission: a lifetime risk-benefit analysis. PLoS ONE 2016; 11: e0157191.
Chouchana L, Roche D, Narjoz C et al. Screening of TPMT deficiency by phenotyping and genotyping: a retrospective study among 1,500 IBD patients in France. Gastroenterology 2011; 140: S281-S282.
Chevaux J-B, Peyrin-Biroulet L, Sparrow MP. Optimizing thiopurine therapy in inflammatory bowel disease. Inflamm. Bowel Dis. 2011 Jun; 17: 1428-1435.
Kham SKY, Soh CK, Liu TC et al. Thiopurine S-methyltransferase activity in three major Asian populations: a population-based study in Singapore. Eur. J. Clin. Pharmacol. 2008; 64: 373-379.
Yang SK, Hong M, Baek J et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat. Genet. 2014; 46: 1017-1020.
Takatsu N, Matsui T, Murakami Y et al. Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. J. Gastroenterol. Hepatol. 2009; 24: 1258-1264.
Fangbin Z, Xiang G, Minhu C et al. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease? Ther. Drug Monit. 2012; 34: 695-701.
Moriyama T, Nishii R, Perez-Andreu V et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat. Genet. 2016; 48: 367-373.
Yang JJ, Landier W, Yang W et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J. Clin. Oncol. 2015; 33: 1235-1242.
Zhang AL, Yang J, Wang H, Lu JL, Tang S, Zhang XJ. Association of NUDT15 c.415C>T allele and thiopurine-induced leukocytopenia in Asians: a systematic review and meta-analysis. Ir. J. Med. Sci. 2018 Feb; 187: 145-153.
Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Ainsworth MA. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand. J. Gastroenterol. 2011; 46: 310-318.
Bortlik M, Duricova D, Malickova K et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. J. Crohns Colitis 2013; 7: 736-743.
Adedokun OJ, Sandborn WJ, Feagan BG et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology 2014; 147: 1296-1307.e5.
Levesque BG, Greenberg GR, Zou G et al. A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. Aliment. Pharmacol. Ther. 2014; 39: 1126-1135.
Vande Casteele N, Khanna R, Levesque BG et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut 2015; 64: 1539-1545.
Reinisch W, Colombel JF, Sandborn WJ et al. Factors associated with short- and long-term outcomes of therapy for Crohn's disease. Clin. Gastroenterol. Hepatol. 2015; 13: 539-547.
Vande Casteele N, Ferrante M, Van Assche G et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015; 148: 1320-1329.e3.
Karmiris K, Paintaud G, Noman M et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009; 137: 1628-1640.
Roblin X, Marotte H, Rinaudo M et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin. Gastroenterol. Hepatol. 2014; 12: 80-84.
Mazor Y, Almog R, Kopylov U et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease. Aliment. Pharmacol. Ther. 2014; 40: 620-628.
Roblin X, Rinaudo M, Del Tedesco E et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am. J. Gastroenterol. 2014; 109: 1250-1256.
Morita Y, Imaeda H, Nishida A et al. Association between serum adalimumab concentrations and endoscopic disease activity in patients with Crohn's disease. J. Gastroenterol. Hepatol. 2016 Nov; 31: 1831-1836.
Ungar B, Levy I, Yavne Y et al. Optimizing anti-TNF-α therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. Clin. Gastroenterol. Hepatol. 2016; 14: 550-557.
Yanai H, Lichtenstein L, Assa A et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin. Gastroenterol. Hepatol. 2015; 13: 522-530.
Vande Casteele N, Gils A, Singh S et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am. J. Gastroenterol. 2013; 108: 962-971.
Dignass A, Van Assche G, Lindsay JO et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J. Crohn's Colitis [Internet]. 2010; 4: 28-62.
Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995; 37: 674-678.
Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. N. Engl. J. Med. [Internet]. 1980 May 1; 302: 981-987.
Dubinsky MC, Lamothe S, Yang HY et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-713.
Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006; 130: 1047-1053.
Hindorf U, Lindqvist M, Hildebrand H, Fagerberg U, Almer S. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2006; 24: 331-342.
Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J. Gastroenterol. Hepatol. 2005; 20: 1149-1157.
Haines ML, Ajlouni Y, Irving PM et al. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm. Bowel Dis. 2011; 17: 1301-1307.
Kennedy NA, Asser TL, Mountifield RE, Doogue MP, Andrews JM, Bampton PA. Thiopurine metabolite measurement leads to changes in management of inflammatory bowel disease. Intern. Med. J. 2013; 43: 278-286.
Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 2003; 348: 601-608.
Yarur AJ, Kubiliun MJ, Czul F et al. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin. Gastroenterol. Hepatol. 2015; 13: 1118-1124.e3.
Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30: 2212-2219.
Cheon JH. Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease. J. Gastroenterol. Hepatol. 2017 Apr; 32: 769-777.
Rahier JF, Magro F, Abreu C et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J. Crohns Colitis 2014; 8: 443-468.
Loras C, Gisbert JP, Mínguez M et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010; 59: 1340-1346.
Park SH, Yang S-K, Lim Y-S et al. Clinical courses of chronic hepatitis B virus infection and inflammatory bowel disease in patients with both diseases. Inflamm. Bowel Dis. 2012; 18: 2004-2010.
Lin JN, Lai CH, Chen YH et al. Risk factors for extra-pulmonary tuberculosis compared to pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 2009; 13: 620-625.
Kulchavenya E. Extrapulmonary tuberculosis: are statistical reports accurate? Ther. Adv. Infect. Dis. 2014 Apr; 2: 61-70.
Lim CH, Chen H-H, Chen Y-H et al. The risk of tuberculosis disease in rheumatoid arthritis patients on biologics and targeted therapy: a 15-year real world experience in Taiwan. PLoS ONE 2017; 12: e0178035.
Weng M-T, Wei S-C, Lin C-C et al. Seminar report from the 2014 Taiwan Society of Inflammatory Bowel Disease (TSIBD) Spring Forum (May 24th, 2014): Crohn's disease versus intestinal tuberculosis infection. Intest. Res. 2015; 13: 6-10.
Horsburgh CR, Rubin EJ. Latent tuberculosis infection in the United States. N. Engl. J. Med. 2011; 364: 1441-1448.
Lee J, Kim E, Jang EJ et al. Efficacy of treatment for latent tuberculosis in patients undergoing treatment with a tumor necrosis factor antagonist. Ann. Am. Thorac. Soc. 2017; 14: 690-697.
Il PD, Hisamatsu T, Chen M et al. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management. J. Gastroenterol. Hepatol. 2018; 33: 30-36.
Naderi HR, Sheybani F, Rezaei Pajand S. How should we manage latent tuberculosis infection in patients receiving anti-TNF-α drugs: literature review. Iran. Red Crescent Med. J. 2016; 18: e27756.
Demir S, Sadi Aykan F, Oztuna D. Latent tuberculosis treatment results in patients that taken TNF-alpha blockers at Ankara Numune Training and Research Hospital Chest Diseases Clinic for last 8 years (2006-2013). Tuberk. Toraks 2014; 62: 286-290.